Glucotoxicity and β-cell failure in type 2 diabetes mellitus

Journal of Pediatric Endocrinology and Metabolism

Volumn 16, Issue 1, 2003, Pages 5-22

  Kaiser, Nurit ^a   Leibowitz, Gil ^a   Nesher, Rafael ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Glucotoxicity; Hyperglycemia; Insulin gene transcription; Insulin secretion; Reactive oxygen species; cell; cell apoptosis; cell mass; cell proliferation

Indexed keywords

GLUCOSE; INSULIN; TRANSCRIPTION FACTOR;

APOPTOSIS; CELL FUNCTION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); GENETIC TRANSCRIPTION; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SYNTHESIS; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ONSET AGE; PANCREAS ISLET BETA CELL; PHYSICAL SENSITIVITY; REGULATORY MECHANISM; REVIEW; STIMULUS RESPONSE; ANIMAL; BIOSYNTHESIS; CELL SURVIVAL; PANCREAS ISLET; PATHOPHYSIOLOGY; SECRETION;

ANIMALS; CELL SURVIVAL; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; INSULIN; ISLETS OF LANGERHANS;

EID: 0038825044     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2003.16.1.5     Document Type: Review

References (138)

1. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
2. Laron Z. Type 2 diabetes mellitus in childhood - a global perspective. J Pediatr Endocrinol Metab 2002; 15 (Suppl 1): 459-469.
3. Cerasi E. Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Diabetologia 1995; 38: 992-997.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
5. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794.
6. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte DJ. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987; 30: 698-702.
7. Glaser B, Leibovich G, Nesher R, Hartling S, Binder C, Cerasi E. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Acta Endocrinol (Copenh) 1988; 118: 365-373.
8. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997; 20: 1353-1356.
9. Yoshioka N, Kuzuya T, Matsuda A, Iwamoto Y. Effects of dietary treatment on serum insulin and pro-insulin response in newly diagnosed NIDDM. Diabetes 1989; 38: 262-266.
10. Poitout V, Robertson RP. Secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002; 143: 339-342.
11. Liang Y, Matschinsky FM. Mechanisms of action of nonglucose insulin secretagogues. Annu Rev Nutr 1994; 14: 59-81.
12. Lang J. Molecular mechanism and regulation of insulin exocytosis as a paradigm of endocrine secretion. Eur J Biochem 1999; 259: 3-17.
13. Watson EL. GTP-binding proteins and regulated exocytosis. Crit Rev Oral Biol Med 1999; 10: 284-306.
14. Daniel S, Noda M, Straub SG, Sharp GW. Identification of the docked granule pool responsible for the first phase of glucose-stimulated insulin secretion. Diabetes 1999; 48: 1686-1690.
15. Gerst JE. SNAREs and SNARE regulators in membrane fusion and exocytosis. Cell Mol Life Sci 1999; 55: 707-734.
16. Sudhof TC. The synaptic vesicle cycle revisited. Neuron 2000; 28: 317-320.
17. Wieland F, Harter C. Mechanisms of vesicle formation: insights from the COP system. Curr Opin Cell Biol 1999; 11: 440-446.
18. Tooze SA, Martens GJ, Huttner WB. Secretory granule biogenesis: rafting to the SNARE. Trends Cell Biol 2001; 11: 116-122.
19. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 2001; 44: 929-945.
20. Porte D Jr, Kahn SE. The key role of islet dysfunction in type II diabetes mellitus. Clin Invest Med 1995; 18: 247-254.
21. Kahn S. Regulation of beta-cell function in vivo. Diabetes Rev 1996; 4: 372-389.
22. Temple RC, Carrington CA, Luzio SD, Owens DR, Schneider AE, Sobey WJ, Hales CN. Insulin deficiency in non-insulin-dependent diabetes. Lancet 1989; i: 293-295.
23. Alcolado JC, Laji K, Gill-Randall R. Maternal transmission of diabetes. Diabet Med 2002; 19: 89-98.
24. Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2001; 414: 788-791.
25. Fletcher B, Gulanick M, Lamendola C. Risk factors for type 2 diabetes mellitus. J Cardiovasc Nurs 2002; 16: 17-23.
26. Lindsay RS, Bennett PH. Type 2 diabetes, the thrifty phenotype - an overview. Br Med Bull 2001; 60: 21-32.
27. Leahy JL, Cooper HE, Deal DA, Weir GC. Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions. J Clin Invest 1986; 77: 908-915.
28. Leahy JL, Bonner-Weir S, Weir GC. Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy. J Clin Invest 1988; 81: 1407-1414.
29. Leahy JL, Bumbalo LM, Chen C. Diazoxide causes recovery of beta-cell glucose responsiveness in 90% pancreatectomized diabetic rats. Diabetes 1994; 43: 173-179.
30. Sako Y, Grill VE. Coupling of beta-cell desensitization by hyperglycemia to excessive stimulation and circulating insulin in glucose-infused rats. Diabetes 1990; 39: 1580-1583.
31. Bolaffi J, Heldt A, Lewis L, Grodsky G. The third phase of in vitro insulin secretion: evidence for glucose insensitivity. Diabetes 1986; 35: 370-373.
32. Bjorklund A, Grill V. B-cell insensitivity in vitro: reversal by diazoxide entails more than one event in stimulus-secretion coupling. Endocrinology 1993; 132: 1319-1328.
33. Kaiser N, Corcos AP, Tur-Sinai A, Ariav Y, Cerasi E. Monolayer culture of adult pancreatic islets on extra-cellular matrix: long term maintenance of differentiated β-cell function. Endocrinology 1988; 123: 834-840.
34. Kaiser N, Corcos AP, Sarel I, Cerasi E. Monolayer culture of adult rat pancreatic islets on extracellular matrix: modulation of B-cell function by chronic exposure to high glucose. Endocrinology 1991; 129: 2067-2076.
35. Purrello F, Verti M, Gatta C, Gullo D, Vigneri R. Effects of high glucose on insulin secretion by isolated rat islets and purified β-cells and possible role of glycosylation. Diabetes 1989; 38: 1417-1422.
36. Davalli AM, Pontiroli AE, Socci C, Bertuzzi F, Fattor B, Braghi S, Di Carlo V, Pozza G. Human islets chronically exposed in vitro to different stimuli become unresponsive to the same stimuli given acutely: evidence supporting specific desensitization rather than beta-cell exhaustion. J Clin Endocrinol Metab 1992; 74: 790-794.
37. Kalderon B, Gutman A, Levy E, Shafrir E, Adler JH. Characterization of stages in development of obesity-diabetes syndrome in the sand rat (Psammomys obesus). Diabetes 1986; 35: 717-723.
38. Kalman R, Ziv E, Adler JH, Lazarovici G, Bar-On H. The efficiency of the sand rat metabolism is responsible for the development of obesity and diabetes. J Basic Clin Physiol Pharmacol 1993; 4: 57-68.
39. Gadot M, Leibowitz G, Shafrir E, Cerasi E, Gross DJ, Kaiser N. Hyperproinsulinemia and insulin deficiency in the diabetic Psammomys obesus. Endocrinology 1994; 135: 610-616.
40. Gadot M, Ariav Y, Cerasi E, Kaiser N, Gross DJ. Hyperproinsulinemia in the diabetic Psammomys obesus is a result of increased secretory demand on the B-cell. Endocrinology 1995; 136: 4218-4223.
41. Nesher R, Gross DJ, Donath MY, Cerasi E, Kaiser N. Interaction between genetic and dietary factors determines β-cell function in Psammomys obesus, an animal model of type 2 diabetes. Diabetes 1999; 48: 731-737.
42. Donath MY, Gross DJ, Cerasi E, Kaiser N. Hyperglycemia-induced β cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 1999; 48: 738-744.
43. Kalman R, Lazarovici G, Bar-On H, Ziv E. The sand rat (Psammomys obesus): morphologic, physiologic and biochemical characteristics of a model for type II diabetes mellitus. Contemp Top Lab Animal Sci 1996; 35: 67-70.
44. Nesher R, Gross DJ, Donath MY, Cerasi E, Kaiser N. Interaction between genetic and dietary factors determines beta-cell function in Psammomys obesus, an animal model of type 2 diabetes. Diabetes 1999; 48: 731-737.
45. Nesher R, Warwar N, Khan A, Efendic S, Cerasi E, Kaiser N. Defective stimulus-secretion coupling in islets of Psammomys obesus, an animal model for type 2 diabetes. Diabetes 2001; 50: 308-314.
46. Leahy JL, Bumbalo LM, Chen C. Beta-cell hypersensitivity for glucose precedes loss of glucose-induced insulin secretion in 90% pancreatectomized rats. Diabetologia 1993; 36: 1238-1244.
47. Rabuazzo AM, Patane G, Anello M, Piro S, Vigneri R, Purrello F. Hexokinase shift to mitochondria is associated with an increased sensitivity to glucose in rat pancreatic islets. Diabetes 1997; 46: 1148-1152.
48. Hosokawa H, Hosokawa YA, Leahy JL. Upregulated hexokinase activity in isolated islets from diabetic 90% pancreatectomized rats. Diabetes 1995; 44: 1328-1333.
49. Wang H, Iynedjian PB. Modulation of glucose responsiveness of insulinoma beta-cells by graded over-expression of glucokinase. Proc Natl Acad Sci USA 1997; 94: 4372-4377.
50. Jonas J-C, Sharma A, Hasenkamp W, Ilkova H, Patane G, Laybutt R, Bonner-Weir S, Weir GC. Chronic hyperglycemia triggers loss of pancreatic β-cell differentiation in an animal model of diabetes. J Biol Chem 1999; 274: 14112-14121.
51. Pertusa JAG, Nehser R, Kaiser N, Cerasi E, Henquin J-C, Jonas J-C. Increased glucose sensitivity of stimulus-secretion coupling in islets from Psammomys obesus after diet induction of diabetes. Diabetes 2002; 51: 2552-2560.
52. Nesher R, Anteby E, Yedovizky M, Warwar N, Kaiser N, Cerasi E. Beta-cell protein kinases and the dynamics of the insulin response to glucose. Diabetes 2002; 51 (Suppl 1): S68-73.
53. Yedovitzky M, Mochly-Rosen D, Johnson JA, Gray MO, Ron D, Abramovitch E, Cerasi E, Nesher R. Translocation inhibitors define specificity of protein kinase C isoenzymes in pancreatic beta-cells. J Biol Chem 1997; 272: 1417-1420.
54. Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 1999; 22: 1543-1548.
55. Tajiri Y, Moller C, Grill V. Long-term effects of aminoguanidine on insulin release and biosynthesis: evidence that the formation of advanced glycosylation end products inhibits B cell function. Endocrinology 1997; 138: 273-280.
56. Spitaler MM, Graier WF. Vascular targets of redox signalling in diabetes mellitus. Diabetologia 2002; 45: 476-494.
57. Lenzen S, Drinkgern J, Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med 1996; 20: 463-466.
58. Ihara Y, Toyokuni S, Uchida K, Odaka H, Tanaka T, Ikeda H, Hiai H, Seino Y, Yamada Y. Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes 1999; 48: 927-932.
59. Tanaka Y, Gleason CE, Tran PO, Harmon JS, Robertson RP. Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci USA 1999; 96: 10857-10862.
60. Sakuraba H, Mizukami HNY, Wada R, Hanyu C, Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islets of Japanese type II diabetic patients. Diabetologia 2002; 45: 85-96.
61. Kaneto H, Xu G, Song KH, Suzuma K, Bonner-Weir S, Sharma A, Weir GC. Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress. J Biol Chem 2001; 276: 31099-31104.
62. Docherty K, Clark AR. Nutrient regulation of insulin gene expression. FASEB J 1994; 8: 20-27.
63. Gross DJ, Leibowitz G, Cerasi E, Kaiser N. Increased susceptibility of islets from diabetes-prone Psammomys obesus to the deleterious effects of chronic glucose exposure. Endocrinology 1996; 137: 5610-5615.
64. Marshak S, Leibowitz G, Bertuzzi F, Socci C, Kaiser N, Gross DJ, Cerasi E, Melloul D. Impaired beta-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. Diabetes 1999; 48: 1230-1236.
65. Harmon JS, Gleason CE, Tanaka Y, Oseid EA, Hunter-Berger KK, Robertson RP. In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes 1999; 48: 1995-2000.
66. Zangen DH, Bonner-Weir S, Lee CH, Latimer JB, Miller CP, Habener JF, Weir GC. Reduced insulin, GLUT2, and IDX-1 in beta-cells after partial pancreatectomy. Diabetes 1997; 46: 258-264.
67. Harmon JS, Gleason CE, Tanaka Y, Poitout V, Robertson RP. Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes 2001; 50: 2481-2486.
68. Goodge KA, Hutton JC. Translational regulation of proinsulin biosynthesis and proinsulin conversion in the pancreatic beta-cell. Semin Cell Dev Biol 2000; 11: 235-242.
69. Melloul D, Marshak S, Cerasi E. Regulation of insulin gene transcription. Diabetologia 2002; 45: 309-326.
70. Jarrett RJ, Keen H, Track N. Glucose and RNA synthesis in mammalian islets of Langerhans. Nature 1967; 213: 634-635.
71. Permutt MA, Kipnis DM. Insulin biosynthesis. I. On the mechanism of glucose stimulation. J Biol Chem 1972; 247: 1194-1199.
72. Welsh M, Scherberg N, Gilmore R, Steiner DF. Translational control of insulin biosynthesis. Evidence for regulation of elongation, initiation and signal-recognition-particle-mediated translational arrest by glucose. Biochem J 1986; 235: 459-467.
73. Itoh N, Sei T, Nose K, Okamoto H. Glucose stimulation of the proinsulin synthesis in isolated pancreatic islets without increasing amount of proinsulin mRNA. FEBS Lett 1978; 93: 343-347.
74. Wicksteed B, Herbert TP, Alarcon C, Lingohr MK, Moss LG, Rhodes CJ. Cooperativity between the preproinsulin mRNA untranslated regions is necessary for glucose-stimulated translation. J Biol Chem 2001; 276: 22553-22558.
75. Shalev A, Blair PJ, Hoffmann SC, Hirshberg B, Peculis BA, Harlan DM. A proinsulin gene splice variant with increased translation efficiency is expressed in human pancreatic islets. Endocrinology 2002; 143: 2541-2547.
76. Nielsen DA, Welsh M, Casadaban MJ, Steiner DF. Control of insulin gene expression in pancreatic beta-cells and in an insulin-producing cell line, RIN-5F cells. I. Effects of glucose and cyclic AMP on the transcription of insulin mRNA. J Biol Chem 1985; 260: 13585-13589.
77. Welsh M, Nielsen DA, MacKrell AJ, Steiner DF. Control of insulin gene expression in pancreatic beta-cells and in an insulin-producing cell line, RIN-5F cells. II. Regulation of insulin mRNA stability. J Biol Chem 1985; 260: 13590-13594.
78. Leibiger B, Moede T, Schwarz T, Brown GR, Kohler M, Leibiger IB, Berggren PO. Short-term regulation of insulin gene transcription by glucose. Proc Natl Acad Sci USA 1998; 95: 9307-9312.
79. Leibiger B, Wahlander K, Berggren P-O, Leibiger IB. Glucose-stimulated insulin biosynthesis depends on insulin-stimulated insulin gene transcription. J Biol Chem 2000; 275: 30153-30156.
80. Leibowitz G, Uckaya G, Oprescu AI, Cerasi E, Gross DJ, Kaiser N. Glucose-regulated proinsulin gene expression is required for adequate insulin production during chronic glucose exposure. Endocrinology 2002; 143: 3214-3220.
81. Leibowitz G, Yuli M, Donath MY, Nesher R, Melloul D, Cerasi E, Gross DJ, Kaiser N. β-Cell glucotoxicity in the Psammomys obesus model of type 2 diabetes. Diabetes 2001; 50 (Suppl 1): S113-S117.
82. German MS, Wang J. The insulin gene contains multiple transcriptional elements that respond to glucose. Mol Cell Biol 1994; 14: 4067-4075.
83. Hwung YP, Gu YZ, Tsai MJ. Cooperativity of sequence elements mediates tissue specificity of the rat insulin II gene. Mol Cell Biol 1990; 10: 1784-1788.
84. Sharma A, Stein R. Glucose-induced transcription of the insulin gene is mediated by factors required for β-cell-type-specific expression. Mol Cell Biol 1994; 14: 871-879.
85. Sharma A, Fusco-DeMane D, Henderson E, Efrat S, Stein R. The role of the insulin control element and RIPE3b1 activators in glucose-stimulated transcription of the insulin gene. Mol Endocrinol 1995; 9: 1468-1476.
86. Marshak S, Totary H, Cerasi E, Melloul D. Purification of the beta-cell glucose-sensitive factor that transactivates the insulin gene differentially in normal and transformed islet cells. Proc Natl Acad Sci USA 1996; 93: 15057-15062.
87. Edlund H. Perspectives in Diabetes. Transcribing pancreas. Diabetes 1998; 47: 1817-1823.
88. Edlund. H. Organogenesis: pancreatic organogenesis developmental mechanisms and implications for therapy. Nat Rev Genet 2002; 3: 524-532.
89. Jonsson J, Carlsson L, Edlund T, Edlund H. Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 1994; 371: 606-609.
90. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 1997; 15: 106-110.
91. Ahlgren U, Jonsson J, Jonsson L, Simu K, Edlund H. Beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev 1998; 15: 1763-1768.
92. Miller CP, McGehee RE, Habener JF. IDX-1: a new homeodomain transcription factor expressed in rat pancreatic islets and duodenum that transactivates the somatostatin gene. EMBO J 1994; 13: 1145-1156.
93. Melloul D, Ben-Neriah Y, Cerasi E. Glucose modulates the binding of an islet-specific factor to a conserved sequence within the rat I and the human insulin promoters. Proc Natl Acad Sci USA 1993; 90: 3865-3869.
94. Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidyl-inositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999; 42: 856-864.
95. Wang X, Cahill CM, Pineyro MA, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 regulates the beta cell transcription factor PDX-1 in insulinoma cells. Endocrinology 1999; 140: 4904-4907.
96. Gremlich S, Bonny C, Waeber G, Thorens B. Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin levels. J Biol Chem 1997; 272: 30261-30269.
97. Habener JF, Stoffers DA. A newly discovered role of transcription factors involved in pancreas development and the pathogenesis of diabetes mellitus. Proc Assoc Am Physicians 1998; 110: 12-21.
98. Macfarlane WM, Campbell SC, Elrick LJ, Oates V, Bermano G, Lindley KJ, Aynsley-Green A, Dunne MJ, James RF, Docherty K. Glucose regulates islet amyloid polypeptide gene transcription in a PDX1- and calcium-dependent manner. J Biol Chem 2000; 19: 15330-15335.
99. Hart AW, Baeza N, Apelqvist A, Edlund H. Attenuation of FGF signalling in mouse beta-cells leads to diabetes. Nature 2000; 14: 864-868.
100. Chakrabarti SK, James JC, Mirmira RG. Quantitative assessment of gene targeting in vitro and in vivo by the pancreatic transcription factor, Pdx1. Importance of chromatin structure in directing promoter binding. J Biol Chem 2002; 277: 13286-13293.
101. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet 1997; 17: 138-139.
102. Macfarlane WM, Frayling TM, Ellard S, Evans JC, Allen LIS, Bulman MP, Ayres S, Shepherd M, Clark P, Millward A, Demaine A, Wilkin T, Docherty K, Hattersley AT. Missense mutations in the insulin promoter factor-1 gene predispose to type 2 diabetes. J Clin Invest 1999; 104: R33-R39.
103. Hani EH, Stoffers DA, Chevre J-C, Durand E, Stanojevic V, Dina C, Habener JF, Froguel P. Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. J Clin Invest 1999; 104: R41-R48.
104. Seufert J, Weir GC, Habener JF. Differential expression of the insulin gene transcriptional repressor CCAAT/enhancer-binding protein beta and transactivator islet duodenum homeobox-1 in rat pancreatic beta cells during the development of diabetes mellitus. J Clin Invest 1998; 101: 2528-2539.
105. Leibowitz G, Ferber S, Apelqvist A, Edlund H, Gross DJ, Cerasi E, Melloul D, Kaiser N. IPF1/PDX1 deficiency and beta-cell dysfunction in Psammomys obesus, an animal with type 2 diabetes. Diabetes 2001; 50: 1799-1806.
106. Olson LK, Sharma A, Peshavaria M, Wright CV, Towle HC, Robertson RP, Stein R. Reduction of insulin gene transcription in HIT-T15 beta cells chronically exposed to a supraphysiologic glucose concentration is associated with loss of STF-1 transcription factor expression. Proc Natl Acad Sci USA 1995; 92: 9127-9131.
107. Sharma A, Olson LK, Robertson RP, Stein R. The reduction of insulin gene transcription in HIT-T15 beta cells chronically exposed to high glucose concentration is associated with the loss of RIPE3b1 and STF-1 transcription factor expression. Mol Endocrinol 1995; 9: 1127-1134.
108. Harmon JS, Tanaka Y, Olson LK, Robertson RP. Reconstitution of glucotoxic HIT-T15 cells with somatostatin transcription factor-1 partially restores insulin promoter activity. Diabetes 1998; 47: 900-904.
109. Lu M, Seufert J, Habener JF. Pancreatic β-cell specific repression of insulin gene transcriprtion by CCAAT/enhancer-binding protein β: inhibitory interactions with basic helix-loop-helix transcription factor E47. J Biol Chem 1997; 272: 28349-28359.
110. Matsuoka T, Kajimoto Y, Watada H, Kaneto H, Kishimoto M, Umayahara Y, Fujitani Y, Kamada T, Kawamori R, Yamasaki Y. Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Invest 1997; 99: 144-150.
111. Kajimoto Y, Matsuoka T, Kaneto H, Watada H, Fujitani Y, Kishimoto M, Sakamoto K, Matsuhisa M, Kawamori R, Yamasaki Y, Hori M. Induction of glycation suppresses glucokinase gene expression in HIT-T15 cells. Diabetologia 1999; 42: 1417-1424.
112. Bonner-Weir S. Islet growth and development in the adult. J Mol Endocrinol 2000; 24: 297-302.
113. Bonner-Weir S. Regulation of pancreatic β-cell mass in vivo. Rec Prog Horm Res 1994; 49: 91-104.
114. Finegood DT, Scaglia L, Bonner-Weir S. Dynamics of β-cell mass in the growing rat pancreas: estimation with a simple mathematical model. Diabetes 1995; 44: 249-256.
115. Bonner-Weir S, Deery D, Leahy JL, Weir GC. Compensatory growth of pancreatic β-cells in adult rats after short-term glucose infusion. Diabetes 1989; 38: 49-53.
116. Schuppin GT, Bonner-Weir S, Montana E, Kaiser N, Weir GC. Replication of adult pancreatic beta cells cultured on bovine corneal endothelial cell extracellular matrix. In Vitro Cell Dev Biol 1993; 29A: 339-344.
117. Bernard C, Berthault MF, Saulnier C, Ktorza A. Neogenesis versus apoptosis as main components of pancreatic β-cell mass changes in glucose-infused mormal and mildly diabetic adult rats. FASEB J 1999; 13: 1195-1205.
118. Maedler K, Spinas GA, Lehmann R, Sergeev P, Weber M, Fontana A, Kaiser N, Donath MY. Glucose induces β-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes 2001; 50: 1683-1690.
119. Federici M, Hribal M, Perego L, Ranalli M, Caradonna Z, Perego C, Usellini L, Nano R, Bonini P, Bertuzzi F, Marlier LN, Davalli AM, Carandente O, Pontiroli AE, Melino G, Marchetti P, Lauro R, Sesti G, Folli F. High glucose causes apoptosis in cultured human pancreatic islets of Langerhans. A potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes 2001; 50: 1290-1301.
120. 2+ concentration. J Biol Chem 1998; 273: 33501-33507.
121. Piro S, Anello M, Di Pietro C, Lizzio MN, Patane G, Rabuazzo AM, Vigneri R, Purrello M, Purrello F. Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress. Metabolism 2002; 51: 1340-1347.
122. Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
123. Stefan Y, Orci L, Malaisse-Lagae F, Perrelet A, Patel Y, Unger R. Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. Diabetes 1982; 31: 694-700.
124. Sempoux C, Guiot Y, Dubois D, Moulin P, Rahier J. Human type 2 diabetes. Morphological evidence for abnormal β-cell function. Diabetes 2001; 50 (Suppl 1): S172-S177.
125. Gepts W, Lecompte P. The pancreatic islets in diabetes. Am J Med 1981; 70: 105-115.
126. Kloppel G, Lohr M, Hablich K, Oberhilzer M, Heinz PU. Islet pathology and pathogenesis of type I and type II diabetes mellitus revisited. Surv Synth Path Res 1985; 4: 110-125.
127. Seito K, Yaginuma N, Takahashi T. Differential volumetry of A, B and D cells in the pancreatic islets of diabetic and nondiabetic subjects. Tohoku J Exp Med 1979; 129: 273-283.
128. Westermark P, Wilander E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 1978; 15: 417-421.
129. Lorenzo A, Razzaboni B, Weir GC, Yankner BA. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994; 368: 756-760.
130. Clark A, Wells C, Buley I, Cruisckshank J, Vanhegan R, Matthews D, Cooper G, Holman R, Turner C. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 1988; 9: 151-159.
131. Jaikaran ETAS, Clark A. Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta 2001; 1537: 179-203.
132. Kaneto H, Fujii J, Myint T, Miyazawa N, Islam KN, Kawasaki YS, Suzuki K, Nakamura M, Tatsumi H, Yamasaki Y, Taniguchi N. Reducing sugars trigger oxidative modification and apoptosis in pancreatic β-cells by provoking oxidative stress through the glycation reaction. Biochem J 1996; 320: 855-863.
133. Koyama M, Wada R, Sakuraba H, Mizukami H, Yagihashi S. Accelerated loss of islet b cells in sucrose-fed Goto-Kakizaki rats, a genetic model of non-insulin-dependent diabetes mellitus. Am J Pathol 1998; 153: 537-545.
134. Bar-On H, Ben-Sasson R, Ziv E, Arar N, Shafrir E. Irreversibility of nutritionally induced NIDDM in Psammomys obesus is related to beta-cell apoptosis. Pancreas 1999; 18: 259-265.
135. Yuli M, Donath MY, Cerasi E, Kaiser N. Normalization of blood glucose in Psammomys obesus corrects β-cell dysfunction and islet morphology. Diabetologia 2000; 43 (Suppl 1): A65.
136. Kaneto H, Kajimoto Y, Miyagawa J-I, Matsuoka T-A, Fujitani Y, Umayahara Y, Hanafusa T, Matsuzawa Y, Yamasaki Y, Hori M. Beneficial effects of antioxidants in diabetes. Possible protection of pancreatic β-cells against glucose toxicity. Diabetes 1999; 48: 2398-2406.
137. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY. Glucose-induced β-cell production of interleukin-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860.
138. Maedler K, Fontana A, Ris F, Sergeev P, Toso C, Oberholzer J, Lehmann R, Bachmann F, Tasinato A, Spinas GA, Halban PA, Donath MY. FLIP switches Fas-mediated glucose signaling in human pancreatic beta cells from apoptosis to cell replication. Proc Natl Acad Sci USA 2002; 99: 8236-8241.